Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial assessing moderate to severe hidradenitis suppurativa.
News|Articles|September 30, 2026
EADV Congress 2026: Day 1 Recap — 6 Headlines to Know
Author(s)Victoria Johnson
Fact checked by: Tim Smith
Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.
Advertisement
Advertisement
Day 1 of the
Related to this article
Intralesional BO-112 met its main endpoint in the phase 2b SPOTLIGHT-204 trial, with 61% of patients with resectable basal cell carcinoma responding.
The international SkinObservatory study found climate-related skin disease disproportionately affecting low-income nations at EADV 2026.
All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.
Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.
Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Zasocitinib achieved PASI 100 in 36.5% of patients vs 13.9% with deucravacitinib at week 16 in the phase 3 LATITUDE Atlas psoriasis trial.
Advertisement
Advertisement